FIELD: biotechnology.
SUBSTANCE: present invention relates to a fused molecule having activity to induce non-inflammatory phagocytosis, wherein the fused molecule comprises: a first portion capable of binding to a TAM receptor, and a second portion which specifically binds to the target substance, the first portion comprising a laminin-G-like domain Gas6 or ProS1 or an active fragment thereof. Also disclosed is a nucleic acid encoding a fused molecule, an expression vector, a cell expressing the fused molecule, and a pharmaceutical composition comprising a fused molecule or an expression vector.
EFFECT: presented invention is effective for induction of non-inflammatory phagocytosis of protein substances, abnormal accumulation of which causes development of diseases.
16 cl, 31 dwg, 8 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
| FUSION PROTEIN CONTAINING HUMAN LEFTY A PROTEIN VARIANTS AND ITS USE | 2019 |
|
RU2793631C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
